PharVision Advisers’s Crocs CROX Stock Holding History

PharVision Advisers’s Portfolio CROX Stock Details CROX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-3,514	Closed	-$356K	–	681
2025 Q2	$356K	Buy	+3,514	New	+$358K	0.51%	39

Other funds holding CROX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WPA

WIT Partners Advisory Singapore $342M AUM 8.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PharVision Advisers's CROX Position: Q3 2025 in Review

PharVision Advisers sold out of Crocs (CROX) in Q3 2025, closing a stake of 3,514 shares — an estimated $356K sold.

PharVision Advisers first reported a position in CROX in Q2 2025 and held it in 1 quarter. The position peaked at $356K in Q2 2025. 476 funds tracked by Wall St. Rank hold CROX as of Q3 2025.

PharVision Advisers reported no remaining Crocs position as of Q3 2025 after selling out during the quarter.
PharVision Advisers sold 3,514 Crocs shares in Q3 2025, an estimated $356K.
PharVision Advisers first reported a position in Crocs in Q2 2025 and held it in 1 quarter.
PharVision Advisers's Crocs position peaked at $356K in Q2 2025.
476 funds tracked by Wall St. Rank held Crocs as of Q3 2025.

Based on PharVision Advisers's 13F filing for Q3 2025, filed 17 Nov 2025.